A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
1 other identifier
interventional
8
1 country
1
Brief Summary
Data collection and assessment on patients with left-sided breast cancer or undergoing lung stereotactic body radiation therapy (SBRT) utilizing continuous positive airway pressure (CPAP) devices.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable lung-cancer
Started Oct 2022
Typical duration for not_applicable lung-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 4, 2021
CompletedFirst Posted
Study publicly available on registry
December 2, 2021
CompletedStudy Start
First participant enrolled
October 19, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 28, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
January 28, 2026
CompletedFebruary 2, 2026
January 1, 2026
3.3 years
October 4, 2021
January 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Dosimetry comparison CPAP and free breathing.
The primary objective will be to assess changes in lung dosimetry V5 on the affected side when using CPAP compared to free breathing will be measured in percentages.
At the time of Scan, " Day 1"
Dosimetry comparison CPAP and free breathing.
The primary objective will be to assess changes in lung dosimetry V20 on the affected side when using CPAP compared to free-breathing will be measured in percentages.
At the time of Scan, " Day 1"
Dosimetry comparison CPAP and free breathing.
The primary objective will be to assess changes in lung dosimetry mean lung on the affected side when using CPAP compared to free-breathing will be measured in Grays.
At the time of Scan, " Day 1"
Secondary Outcomes (5)
Total Lung dosimetry
At the time of Scan, " Day 1"
Cardiac dosimetry with CPAP as compared to free breathing
At the time of Scan, " Day 1"
Measure breast/chest wall or lung tumor motion as well as organ at risk motion
At the time of Scan, " Day 1"
Treatment time with CPAP treatments
At the time of Scan, " Day 1"
Confirm maintenance of inflation with CPAP using surface guidance
At the time of Scan, " Day 1"
Study Arms (2)
left-sided breast cancer
ACTIVE COMPARATORParticipants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
Lung SBRT
ACTIVE COMPARATORParticipants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
Interventions
Use of CPAP device at the start of treatment planning.
Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
Eligibility Criteria
You may qualify if:
- Patients with left-sided breast cancers
- Patients must be undergoing left breast/chest wall radiation with or without regional nodal irradiation
- Patients undergoing lung SBRT
- Primary lung cancers
- Metastatic lung tumors
You may not qualify if:
- Patients with right side breast cancer
- Patients who are unable to tolerate the CPAP device
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Case Comprehensive Cancer Centerlead
- Varian Medical Systemscollaborator
Study Sites (1)
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sheeh Cherian, MD
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 4, 2021
First Posted
December 2, 2021
Study Start
October 19, 2022
Primary Completion
January 28, 2026
Study Completion
January 28, 2026
Last Updated
February 2, 2026
Record last verified: 2026-01